Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 4Depression 4Head and Neck Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Fatigue 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Sleep Wake Disorders 1Recurrence 1Radiation Fibrosis Syndrome 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Acceptance of Health Care 1Pain 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Calculi 1Inflammatory Breast Neoplasms 1Immune Checkpoint Inhibitor-Induced Dermatitis 1Health Education 1Constriction, Pathologic 1

Interventions

Cyclophosphamide 48fludarabine 32Methotrexate 24blinatumomab 20fludarabine phosphate 19Dexamethasone 19Vincristine 18Whole-Body Irradiation 16Specimen Handling 16Cytarabine 16Tacrolimus 14Mycophenolic Acid 14Peripheral Blood Stem Cell Transplantation 13Melphalan 13Mercaptopurine 12Calcium Dobesilate 12merphos 11Busulfan 11Biopsy 11Magnetic Resonance Spectroscopy 10Etoposide 10Stem Cell Transplantation 9Prednisone 9Granulocyte Colony-Stimulating Factor 9Cyclosporine 9Thiotepa 8Rituximab 8Mesna 8Filgrastim 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Therapeutics × 90 days × Clear all
NCT07301424 2026-05-06

Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

University of Alberta

Phase 2 Not yet recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡